XORTX Therapeutics Inc.
XRTX
$0.64
$0.034.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -28.10% | -42.97% | -4.87% | -18.58% | 4.23% |
| Depreciation & Amortization | 13.51% | -16.36% | -19.00% | 6.97% | 56.97% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.06% | -26.19% | 27.68% | -32.68% | -45.32% |
| Operating Income | 21.06% | 26.19% | -27.68% | 32.68% | 45.32% |
| Income Before Tax | -10.65% | -521.93% | 76.86% | -95.46% | 55.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.65% | -521.93% | 76.86% | -95.46% | 55.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.65% | -521.93% | 76.86% | -95.46% | 55.98% |
| EBIT | 21.06% | 26.19% | -27.68% | 32.68% | 45.32% |
| EBITDA | 18.82% | 24.44% | -33.25% | -21.95% | 46.86% |
| EPS Basic | 33.88% | -423.38% | 84.95% | -97.23% | 69.69% |
| Normalized Basic EPS | 33.86% | -423.50% | 84.96% | -97.23% | 69.68% |
| EPS Diluted | 33.88% | -424.23% | 84.71% | -97.24% | 69.82% |
| Normalized Diluted EPS | 33.86% | -423.50% | 84.96% | -97.23% | 69.68% |
| Average Basic Shares Outstanding | 67.26% | 30.47% | 53.83% | 63.88% | 45.27% |
| Average Diluted Shares Outstanding | 67.26% | 30.47% | 53.83% | 63.88% | 45.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |